Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Levels of NfL Increase Accuracy of Stroke Risk Prediction

By LabMedica International staff writers
Posted on 08 Jul 2019
Serum levels of neurofilament light polypeptide have been found to predict the likelihood of suffering a stroke and to add considerably to the discriminatory power of the Framingham Stroke Risk Score in a group of middle-aged and older adults with diabetes mellitus.

Neurofilament light polypeptide (NfL), also known as neurofilament light chain, is a neurofilament protein that in humans is encoded by the NEFL gene. More...
Neurofilament light chain is a biomarker that can be measured with immunoassays in cerebrospinal fluid and blood serum and plasma that reflects axonal damage in a wide variety of neurological disorders. It is a useful marker for disease monitoring in amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and more recently Huntington's disease.

As effective stroke prevention depends on accurate stroke risk prediction, investigators at the University of Michigan (Ann Arbor, USA) examined the discriminative ability of NfL levels for distinguishing between adults with diabetes mellitus who developed incident stroke and those who remained stroke free during a seven-year follow-up period.

The investigators performed a case-control study of participants selected from the previously completed ACCORD trial (Action to Control Cardiovascular Risk in Diabetes). The 113 cases were all ACCORD subjects who were stroke free at enrollment and developed incident stroke during follow-up. A group of 250 control subjects comprised randomly selected ACCORD subjects who had no stroke events either before or after randomization. NfL levels were measured in baseline samples using Quanterix (Billerica, MA, USA) Single Molecule Array technology.

Results revealed that subjects who developed a stroke had blood levels of NfL that were about 43% higher than those who did not develop a stroke. In contrast, those with the highest NfL levels were 10 times more likely to develop a stroke during the seven-year follow-up period, than those with low levels of NfL.

In addition, the results showed that older age, nonwhite race, higher systolic blood pressure, glomerular filtration rate less than 60, and higher hemoglobin A1C were independent predictors of serum NfL in this cohort, but that diastolic blood pressure, durations of hypertension or diabetes mellitus, and lipid levels were not.

First author Dr. Frederick Korley, assistant professor of emergency medicine at the University of Michigan, said, "The Framingham Stroke Risk Score looks at stroke risk factors in a patient and predicts 10-year probability of a stroke occurring. The score currently includes factors such as diabetes, current smoking status, and blood pressure. When we added NfL levels as a risk factor, the score appeared to become even more accurate in predicting stroke."

The NfL study was published in the July 1, 2019, issue of the journal Stroke.

Related Links:
University of Michigan
Quanterix


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.